Biozenta Lifescience Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Biozenta Lifescience Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $113.9K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Biozenta Lifescience Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $113.9K Trade | TransData Nexus

Who is Biozenta Lifescience Private Limited? — Company Overview & Market Position

Biozenta Lifescience Private Limited, established on February 22, 2018, is a privately held pharmaceutical company headquartered in Mumbai, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) U74999MH2018PTC440022 and is registered with the Registrar of Companies (RoC) Mumbai. With an authorized capital of ₹1.00 crore and a paid-up capital of ₹60.00 lakh, Biozenta Lifescience has demonstrated significant growth since its inception. As of March 31, 2023, the company reported a revenue of $3.89 million USD, a net profit of $35,590 USD, and an EBITDA of $1.46 million USD.

The company's operations are managed by a team of directors, including Deep Narayan (Managing Director), Babita Saini, Abhishek Jain, Subodh Saini, Jainendra Kumar Sahu, and Sushil Kumar. As of January 9, 2026, Biozenta Lifescience employed approximately 55 professionals. The company's registered office is located at #7/54, Building No. 7, Anand Nagar Sahayog Cooperative Housing Society Ltd, Nehru Road, Mumbai, Maharashtra, 400055.

What Does Biozenta Lifescience Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Daunorubicin$87.0K 2Mercaptopurine$23.6K 3Mitoxantrone$3.3K

Biozenta Lifescience Private Limited Therapeutic Categories — 1 Specializations

Biozenta Lifescience Private Limited operates across 1 therapeutic categories, with Advanced Oncology (100.0%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.

Advanced Oncology

3 products · 100.0% · $113.9K

Product Portfolio — Top 3 by Export Value

Biozenta Lifescience Private Limited exports 3 pharmaceutical products across 1 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Daunorubicin	Advanced Oncology	$87.0K	6	12.6%	1
2	Mercaptopurine

Key Metrics

Total Trade$113.9K

Products3

Shipments12

Categories1

#1 Rankings1

Top 5 Concentration100.0%

Top Categories

Advanced Oncology100.0%

Top Export Routes

Daunorubicin → COLOMBIA

Last updated: March 28, 2026

Biozenta Lifescience Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Biozenta Lifescience operates a state-of-the-art manufacturing facility in Una, Himachal Pradesh, India. This plant is WHO-cGMP certified and EU GMP approvable, specializing in the production of oncology products, including liquid and lyophilized injections, tablets, and capsules, as well as general injectables such as liquid and lyophilized injections and pre-filled syringes. The facility is strategically located to cater to both domestic and international markets, ensuring compliance with global quality standards.

Where Does Biozenta Lifescience Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Biozenta Lifescience has made significant strides in penetrating regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating adherence to international quality standards. Additionally, Biozenta has secured product registrations in over 30 countries across Asia, Africa, Europe, Latin America, and the GCC, with more than 180 international product registrations. These certifications and registrations facilitate market access and underscore the company's commitment to quality and regulatory compliance.

2Emerging Markets

Biozenta Lifescience has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's WHO-cGMP certified facility and EU GMP approvable status enable it to meet the stringent regulatory requirements of these regions. By obtaining product registrations in over 30 countries, Biozenta has enhanced its ability to participate in government tenders and supply to public health programs, thereby increasing its footprint in these emerging markets.

3Geographic Strategy

Biozenta Lifescience's geographic strategy reflects a balanced approach between diversification and concentration. While the company has established a strong presence in regulated markets such as the US, EU, UK, Australia, and Japan, it has also made significant inroads into emerging markets across Asia, Africa, Europe, Latin America, and the GCC. This dual approach mitigates concentration risk and positions Biozenta to leverage growth opportunities in diverse regions. The company's strategic direction focuses on expanding its global footprint while maintaining high standards of quality and compliance.

TransData Nexus Research · FDA, EMA, WHO, MHRA, TGA databasesMar 2026

Biozenta Lifescience Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 28, 2026, Biozenta Lifescience has not publicly disclosed specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. The company's focus on WHO-cGMP certification and EU GMP approvable status suggests a commitment to meeting international quality standards, which may facilitate future FDA approvals. However, without explicit information, a comprehensive assessment of Biozenta's FDA status cannot be provided.

2WHO & EU GMP

Biozenta Lifescience's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating compliance with international quality standards. These certifications are crucial for market access in regulated regions and reflect the company's commitment to maintaining high manufacturing standards. The EU GMP approvable status further enhances Biozenta's credibility in the European market, positioning it favorably for future collaborations and market expansion.

3CDSCO & Indian Regulatory

Biozenta Lifescience operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, indicating adherence to international quality standards. While specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed, the company's compliance with global standards suggests alignment with Indian regulatory requirements.

4Recent Regulatory Actions

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Biozenta Lifescience by regulatory authorities. The company's adherence to WHO-cGMP and EU GMP standards suggests a proactive approach to regulatory compliance. However, without explicit records, a detailed analysis of recent regulatory actions cannot be provided.

TransData Nexus Research · FDA Orange Book, WHO PQ database, EMA GMP registry, CDSCOMar 2026

Biozenta Lifescience Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology pharmaceutical sector, Biozenta Lifescience faces competition from both domestic and international manufacturers. Key competitors include established Indian pharmaceutical companies with a strong presence in oncology products, as well as multinational corporations operating in the same therapeutic area. While specific market share data is not publicly available, Biozenta's focus on high-quality, affordable oncology medicines positions it as a competitive player in the market. The company's WHO-cGMP certified facility and EU GMP approvable status further enhance its competitive edge.

2Key Differentiators

Biozenta Lifescience's key differentiators include its commitment to innovation, quality, and global reach. The company's manufacturing facility in Una, Himachal Pradesh, is WHO-cGMP certified and EU GMP approvable, ensuring adherence to international quality standards. Additionally, Biozenta has secured product registrations in over 30 countries, with more than 180 international product registrations, reflecting its extensive global presence. These factors collectively contribute to Biozenta's competitive advantages in the pharmaceutical industry.

3Strategic Position

Biozenta Lifescience's current strategic direction focuses on expanding its global footprint while maintaining high standards of quality and compliance. The company's portfolio includes oncology, critical care, APIs, and general injectables, indicating a diversified approach to pharmaceutical manufacturing. Future outlooks suggest continued growth in both regulated and emerging markets, leveraging its WHO-cGMP certified and EU GMP approvable manufacturing facility. The company's commitment to innovation and quality positions it favorably for sustained success in the global pharmaceutical industry.

TransData Nexus Research · DGFT export records, industry analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Supplier Matching: Biozenta Lifescience Private Limited identified across shipments using name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
3.Market Share: Calculated per product as Biozenta Lifescience Private Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 12 individual customs records matching Biozenta Lifescience Private Limited.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

3 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Biozenta Lifescience Private Limited

Biozenta Lifescience Private Limited — Export Portfolio & Destination Treemap

Who is Biozenta Lifescience Private Limited? — Company Overview & Market Position

What Does Biozenta Lifescience Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

Biozenta Lifescience Private Limited Therapeutic Categories — 1 Specializations

Product Portfolio — Top 3 by Export Value

Key Metrics

Top Categories

Top Export Routes

Biozenta Lifescience Private Limited — Corporate Profile & Information

1Corporate Overview

2Manufacturing Facilities

Related Analysis

Need Detailed Data?

3Key Leadership

Where Does Biozenta Lifescience Private Limited Export? — Destination Intelligence

1Regulated Markets

2Emerging Markets

3Geographic Strategy

Biozenta Lifescience Private Limited — Manufacturing & Regulatory Profile

1FDA Status

2WHO & EU GMP

3CDSCO & Indian Regulatory

4Recent Regulatory Actions

Biozenta Lifescience Private Limited — Competitive Positioning Among Indian Pharma Exporters

1Competitive Landscape

2Key Differentiators

3Strategic Position

Buyer Due Diligence Brief — Evaluating Biozenta Lifescience Private Limited as a Supplier

1Supplier Assessment

2Certifications to Verify

Frequently Asked Questions — Biozenta Lifescience Private Limited

How many pharmaceutical products does Biozenta Lifescience Private Limited export from India?

What is Biozenta Lifescience Private Limited's total pharmaceutical export value?

In which products is Biozenta Lifescience Private Limited the #1 Indian exporter?

What therapeutic categories does Biozenta Lifescience Private Limited cover?

Get Full Biozenta Lifescience Private Limited Export Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology